Early Stop on a 12-Arm Checkout Experiment

No. The result is not credible enough to ship because at least three independent problems undermine the p-value. First, the sample-ratio mismatch is severe: control has 4,100 users while most arms have about 3,150, and p<0.001 is unlikely to be chance. That suggests an assignment, logging, redirect, or bot-filtering bug. If the arms differ systematically in who gets logged, the conversion rates are not comparable. Second, the team has peeked daily and discussed stopping when a variant looked good. Repeated looks inflate the false-positive rate; a p=0.04 at an unplanned interim is not the same as p=0.04 at a fixed horizon. Third, 12 arms mean 11 comparisons against control. At alpha 0.05, the probability of at least one false positive is high. A Bonferroni threshold would be about 0.05/11 = 0.0045; the observed 0.04 does not clear it. A false discovery rate procedure would also likely reject it given the small number of arms and modest signal.

The observed 5.9% versus 5.0% is a 0.9-point lift, but with only about 3,150 users per arm the standard error is roughly sqrt(0.050.95/3150 + 0.0590.941/3150) ≈ 0.0059, so the lift is about 1.5 standard errors. That is weak evidence even before multiplicity. The correct conclusion is that the experiment is invalid, not that the variant wins.

The first step is to pause the ship decision and audit randomization and logging. I would check the assignment unit, the hash function or randomization service, exposure logging, redirects, bot filtering, and whether any arm had a different eligibility rule. The mismatch must be explained before conversion rates are interpreted; if it is a logging bug, the data may be recoverable, but if it is an assignment bug, the experiment is compromised. I would also check whether the control arm includes users who never loaded checkout or whether one variant failed to log exposures.

Once the SRM is resolved, the plan should pre-register the primary metric, guardrails, fixed sample size or a sequential design, and the multiplicity correction. The primary analysis should use the randomized assignment unit, intention-to-treat, and a regression adjustment for pre-specified covariates only if pre-registered. For 12 arms, either use a family-wise correction such as Bonferroni or Holm, or use a Bayesian or sequential method with an explicit error budget. The team should not switch methods after seeing the result. If they want early stopping, use group-sequential alpha spending with a pre-specified number of looks. Given the current data, the only defensible action is to fix the pipeline and rerun or continue to the planned sample with a valid analysis plan.

I would recommend not shipping the variant as a confirmed winner. The interim decision could be a limited, time-boxed pilot only if the business accepts that it is an operational test rather than causal evidence, and only after the SRM is explained. Even then, I would not redirect a large share of traffic or make budget commitments based on the 0.04 p-value. The safer interim action is to keep the current checkout, fix the logging and assignment issues, and run a clean experiment with fewer arms and a pre-registered stopping rule.

The communication should be direct: 'The observed lift is interesting but not trustworthy yet because the arms are imbalanced and the result was peeked at across 12 variants. Shipping now risks rolling out a change that may be neutral or harmful.' I would show the SRM check and the multiplicity-adjusted threshold, not just the raw p-value. I would also commit to a concrete next step with a date and owner: audit within two days, then a clean test with, say, four arms and 40,000 users per arm. If leadership overrides and ships, I would document the decision, limit exposure, and monitor guardrail metrics such as revenue per user, refund rate, and checkout error rate so the risk is contained.